As demonstrated in a 2019 randomized, controlled trial, administration of Akkermansia muciniphila led to decreased body weight and fat mass compared with placebo, while also reducing insulin sensitivity, insulinemia, and plasma total cholesterol.15 Clostridium butyricum WB-STR-0006 The gut health benefits of Clostridium butyricum are succinctly laid out in a 2022 review, which describes the species as widely effective against three common GI pathogens: Clostridioides difficile, Helicobacter pylori , and Escherichia coli .16 In the United States alone, these pathogens cause hundreds of thousands of infections every year, plus tens of thousands of deaths.17 18 19 It seems to have anti-obesity effects , too, as rodent studies have shown that it increases levels of gut acids that can suppress appetite and inhibit fat storage.20 Also (to highlight this species name), Clostridium butyricum produces butyrate, a short-chain fatty acid whose levels inversely correlate with risk for inflammatory bowel diseases and positively correlate with improved diabetic biomarkers .21 22 Anaerobutyricum hallii WB-STR-0008 The presence of Anaerobutyricum hallii gives us a second butyrate producer in the Pendulum formula.23 Its moreover a key contributor to the formation of a different short-chain fatty acid called propionate, which is believed to inhibit fat storage and reduce serum cholesterol levels .24 Clostridium beijerinckii WB-STR-0005 Clostridium beijerinckii is another known butyrate producer.25 It furthermore plays a regulatory role in the gut microbiome, keeping harmful bacteria in check while promoting the proliferation of beneficial species
Compounded medications are prepared by licensed pharmacies and are not FDA-approved
Frontiers inendocrinology, 13, 838410
Bioengineered nanomedicines targeting the intestinal fc receptor achieve the improved glucoregulatory effect of semaglutide in a type 2 diabetic mice model
The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
Rare postmarketing reports of intestinal obstruction have also been noted
